Therapy Detail

Therapy Name Ganetespib
Synonym
Therapy Description

Ganetespib is a small molecule that inhibits Hsp90, resulting in the degradation and inactivation of Hsp90 client proteins and decreased cell proliferation (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Ganetespib STA-9090 HSP90 Inhibitor 35 Ganetespib is a small molecule that inhibits Hsp90, resulting in the degradation and inactivation of Hsp90 client proteins and decreased cell proliferation (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable Ganetespib Preclinical - Cell line xenograft Actionable In a preclinical study, Ganetespib demonstrated potent anti-tumor effects against a variety of advanced solid tumor cell types and in cell line xenograft models (PMID: 22144665). 22144665
TP53 R248Q Advanced Solid Tumor sensitive Ganetespib Preclinical Actionable In a preclinical study, Ganetespib extended survival by 48% in mice with tumors expressing TP53 R248Q (PMID: 26009011). 26009011
ERBB2 Y772_A775dup ERBB2 C805S Advanced Solid Tumor predicted - sensitive Ganetespib Preclinical - Cell culture Actionable In a preclinical study, Ganetespib inhibited growth of transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as reported as A775_G776insYVMA) and an acquired ERBB2 (HER2) C805S in culture (PMID: 30527195). 30527195
TP53 S241F ovarian cancer sensitive Ganetespib Preclinical Actionable In a preclinical study, Ganetespib inhibited growth of human ovarian cancer cells harboring TP53 S241F in culture (PMID: 26009011). 26009011
TP53 R280K breast cancer sensitive Ganetespib Preclinical Actionable In a preclinical study, Ganetespib inhibited growth of human breast cancer cells harboring TP53 R280K in culture (PMID: 26009011). 26009011
ERBB2 G776delinsVC ERBB2 C805S Advanced Solid Tumor predicted - sensitive Ganetespib Preclinical - Cell culture Actionable In a preclinical study, Ganetespib inhibited growth of transformed cells expressing ERBB2 (HER2) G776delinsVC and an acquired ERBB2 (HER2) C805S in culture (PMID: 30527195). 30527195
TP53 L194F breast cancer sensitive Ganetespib Preclinical - Cell culture Actionable In a preclinical study, Ganetespib inhibited growth of human breast cancer cells harboring TP53 L194F in culture (PMID: 26009011). 26009011
BRAF V600E skin melanoma sensitive Ganetespib Preclinical - Cell line xenograft Actionable In a preclinical study, the Hsp90 inhibitor Ganetespib destabilized BRAF, especially BRAF V600E, resulted in loss of cell viability in culture and antitumor effects in cell line xenograft models of melanoma (PMID: 24398428). 24398428
ERBB2 Y772_A775dup Advanced Solid Tumor predicted - sensitive Ganetespib Preclinical - Cell culture Actionable In a preclinical study, Ganetespib inhibited growth of transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as reported as A775_G776insYVMA) in culture (PMID: 30527195). 30527195
MET amp non-small cell lung carcinoma predicted - sensitive Ganetespib Preclinical - Cell culture Actionable In a preclinical study, disruption of multiple kinases with Hsp90 inhibitor Ganetespib inhibited survival of MET amplified non-small cell lung cancer cells that acquired resistance to SGX532 through activation of multiple kinase signaling pathways in culture (PMID: 26483207). 26483207
TP53 P223L TP53 V274F prostate cancer resistant Ganetespib Preclinical Actionable In a preclinical study, Ganetespib inhibited growth of human prostate cancer cells harboring TP53 P223L and V274F in culture (PMID: 26009011). 26009011
TP53 R175H breast cancer sensitive Ganetespib Preclinical - Cell culture Actionable In a preclinical study, Ganetespib inhibited growth of human breast cancer cells harboring TP53 R175H in culture (PMID: 26009011). 26009011
Unknown unknown lung small cell carcinoma not applicable Ganetespib Preclinical - Cell line xenograft Actionable In a preclinical study, small cell lung carcinoma cell line xenograft models treated with Ganetespib demonstrated partial tumor growth inhibition, but with tumor progression, weight loss ensued (PMID: 27267850). 27267850
ERBB2 G776delinsVC Advanced Solid Tumor predicted - sensitive Ganetespib Preclinical - Cell culture Actionable In a preclinical study, Ganetespib inhibited growth of transformed cells expressing ERBB2 (HER2) G776delinsVC in culture (PMID: 30527195). 30527195
Clinical Trial Phase Therapies Title Recruitment Status
NCT01560416 Phase II Fulvestrant Ganetespib Fulvestrant With or Without Ganetespib in HR+ Breast Cancer Completed
NCT02389751 Phase I Carboplatin Paclitaxel Ganetespib A Study of Ganetespib in Combination With Chemoradiation Active, not recruiting
NCT01962948 Phase II Paclitaxel Ganetespib Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Terminated
NCT01798485 Phase III Ganetespib Docetaxel A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC Terminated
NCT02334319 Phase I Ganetespib Ganetespib Window of Opportunity Study in Head and Neck Cancers Terminated
NCT02637375 Phase I Cyclophosphamide + Doxorubicin + Paclitaxel Ganetespib A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer Withdrawn
NCT01200238 Phase II Ganetespib STA-9090(Ganetespib) in Metastatic Ocular Melanoma Completed